logo

For the Inventor, By the Inventor

Bothell, WA, United States of America

Seattle Genetics, Inc.


USPTO Granted Patents = 132



Trademarks = 21

Forward Citations = 4,538

Loading Chart...
Loading Chart...

105 inventors (with patents filed for the assignee):

goldMedal Peter Senter (30 out of 47 patents)

silverMedal Svetlana Doronina (28 out of 32 patents)

bronzeMedal Scott C Jeffrey (26 out of 30 patents)

4.  Brian E Toki (24 out of 25 patents)

5.  Patrick J Burke (19 out of 26 patents)

6.  Alan F Wahl (19 out of 19 patents)

7.  Che-Leung Law (15 out of 19 patents)

8.  Django Sussman (13 out of 20 patents)

9.  Dennis R Benjamin (13 out of 24 patents)

10.  Philip Wilson Howard (12 out of 92 patents)

11.  Paul J Carter (12 out of 58 patents)

12.  Toni Beth Kline (11 out of 22 patents)

13.  Charlotte McDonagh (10 out of 13 patents)

14.  Julie A McEarchern (10 out of 12 patents)

15.  Eric Sievers (9 out of 16 patents)


Core Competencies:
Antibody Drug Conjugates
CD30 Antibodies
Pyrrolobenzodiazepines
Cancer Treatment
Monomethylvaline Compounds
Fucosylation Inhibition
CD33 Antibodies
Targeted Conjugates
Engineered-Cysteine Caps
CHO Cell Cultures
Humanized Antibodies
Sickle Cell Disease

132 patents:

1. 11795229 - Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy (2023-10-24),
2. 11299543 - Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment (2022-04-12),
3. 10912842 - CD123 antibodies and conjugates thereof (2021-02-09),
4. 10828375 - Distribution of engineered-cysteine caps (2020-11-10),
5. 10808039 - Monomethylvaline compounds capable of conjugation to ligands (2020-10-20),
6. 10787514 - CD33 antibodies and use of same to treat cancer (2020-09-29),
7. 10722592 - CD48 antibodies and conjugates thereof (2020-07-28),
8. 10722549 - Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates (2020-07-28),
9. 10669348 - Antibody drug conjugates (ADC) that bind to 158P1D7 proteins (2020-06-02),
10. 10561739 - Targeted pyrrolobenzodiazapine conjugates (2020-02-18),
11. 10478469 - Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates (2019-11-19),
12. 10464997 - Selective reduction of proteins (2019-11-05),
13. 10457976 - Preparing antibodies from CHO cell cultures for conjugation (2019-10-29),
14. 10444241 - Detection and treatment of CD30cancers (2019-10-15),
15. 10443035 - Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation (2019-10-15),
Seattle Genetics is a biotechnology company focused on developing innovative antibody-based therapies for the treatment of cancer. The company’s proprietary ADC technology platform allows targeted delivery of potent medicines to cancer cells while sparing healthy tissues. Seattle Genetics is dedicated to improving patient outcomes by advancing the field of precision medicine.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

132 Patents

#3 in Bothell, WA

#47 in Washington

#2,825 in US

#5,929 in the World

...
Bothell, WA, United States of America

Seattle Genetics, Inc.

Forward Citations = 4,538

105 inventors:

goldMedal Peter Senter (30 out of 47 patents)

silverMedal Svetlana Doronina (28 out of 32 patents)

bronzeMedal Scott C Jeffrey (26 out of 30 patents)

4.  Brian E Toki (24 out of 25 patents)

5.  Patrick J Burke (19 out of 26 patents)

Please report any incorrect information to support@idiyas.com
Loading…